| 摘要 |
To address the issue of degradation by enzymatic reactions to proteins and peptides, polyethylene glycol (PEGylation) of the proteins and peptides has been established. PEGylated proteins and peptides have increased plasma half-lives and reduced immunogenicity. To further improve and extend the plasma half-life of desired protein or peptide therapeutics, a novel branched molecule of PEG possessing three PEGs with a single point of attachment is designed in this invention disclosure.
|
